Shimla Online

Dry Eye Disease Pipeline Insight Report: 50+ Companies | DelveInsight

 Breaking News
  • No posts were found

Dry Eye Disease Pipeline Insight Report: 50+ Companies | DelveInsight

November 15
01:00 2022
Dry Eye Disease Pipeline Insight Report: 50+ Companies | DelveInsight

DelveInsight’s, “Dry Eye Disease Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Dry Eye Disease Pipeline Insight Report

  • DelveInsight’s Dry Eye Disease pipeline analysis depicts a robust space with 60+ active players working to develop 60+ pipeline therapies.
  • The leading Dry Eye Disease Companies are working such as TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
  • Promising Dry Eye Disease Pipeline Therapies such as Reproxalap, Timbetasin, Visomitin, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.

 

Recent Breakthroughs of Dry Eye Disease Treatment Landscape

  • In a Phase II b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
  • RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.
  • Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

 

Request a sample and discover the recent advances in Dry Eye Disease Medication @ Dry Eye Disease Treatment Landscape

 

Dry Eye Disease Overview

Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes. Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes. People with dry eyes may experience irritated, gritty, scratchy or burning eyes; a feeling of something in their eyes; excess watering; and blurred vision. Symptoms include: Redness, stinging, scratching, or burning sensations, light sensitivity, watery eyes, stringy mucus near the eye and a blurry Vision. Dry eyes can be diagnosed through a comprehensive eye examination. Treatments for dry eyes aim to restore or maintain the normal amount of tears in the eye to minimize dryness and related discomfort and to maintain eye health. The primary approaches used to manage and treat dry eyes include adding tears using over-the-counter artificial tear solutions, conserving tears, increasing tear production, and treating the inflammation of the eyelids or eye surface that contributes to the dry eyes.

 

Dry Eye Disease Emerging Drugs

  • Reproxalap: Aldeyra Therapeutics
  • Timbetasin: RegeneRx Biopharmaceuticals
  • Visomitin: Mitotech

Dry Eye Disease Pipeline Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.

 

DelveInsight’s Dry Eye Disease Pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Dry Eye Disease pipeline therapies @ Dry Eye Disease Clinical Trials

 

Scope of the Dry Eye Disease Pipeline Report

  • Coverage- Global
  • Dry Eye Disease Pipeline Assessment by Product Type
  • Dry Eye Disease Pipeline Assessment by Stage and Product Type
  • Dry Eye Disease Pipeline Assessment by Route of Administration
  • Dry Eye Disease Pipeline Assessment by Stage and Route of Administration
  • Dry Eye Disease Pipeline Assessment by Molecule Type
  • Dry Eye Disease Pipeline Assessment by Stage and Molecule Type
  • Dry Eye Disease Companies- TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
  • Dry Eye Disease Pipeline Therapies- Reproxalap, Timbetasin, Visomitin, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dry Eye Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dry Eye Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name: Company Name
  9. Last Stage Products (Phase III)
  10. Timbetasin: RegeneRx Biopharmaceuticals
  11. Mid Stage Products (Phase II)
  12. Drug name: Company name
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Dry Eye Disease Key Companies
  17. Dry Eye Disease Key Products
  18. Dry Eye Disease – Unmet Needs
  19. Dry Eye Disease – Market Drivers and Barriers
  20. Dry Eye Disease – Future Perspectives and Conclusion
  21. Dry Eye Disease Analyst Views
  22. Dry Eye Disease Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  1. How many companies are developing Dry Eye Disease drugs?
  2. How many Dry Eye Disease drugs are developed by each company?
  3. How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?
  4. What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?
  5. What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  6. What are the clinical studies going on for Dry Eye Disease and their status?
  7. What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Dry Eye Disease Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles